Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 351

1.

MicroRNA-141 Targets Sirt1 and Inhibits Autophagy to Reduce HBV Replication.

Yang Y, Liu Y, Xue J, Yang Z, Shi Y, Shi Y, Lou G, Wu S, Qi J, Liu W, Chen Z, Wang J.

Cell Physiol Biochem. 2017;41(1):310-322. doi: 10.1159/000456162. Epub 2017 Jan 24.

2.

Screening and diagnosis of HBV in low-income and middle-income countries.

Allain JP, Opare-Sem O.

Nat Rev Gastroenterol Hepatol. 2016 Nov;13(11):643-653. doi: 10.1038/nrgastro.2016.138. Epub 2016 Sep 14. Review.

PMID:
27625189
3.

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.

Kim HJ, Park SK, Yang HJ, Jung YS, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Choi KY.

Clin Mol Hepatol. 2016 Sep;22(3):350-358. Epub 2016 Sep 25.

4.

A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation.

Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, Kita R, Kimura T, Iijima H, Nishiguchi S, Osaki Y.

Medicine (Baltimore). 2016 Sep;95(36):e4832. doi: 10.1097/MD.0000000000004832.

5.

Virus and Host Testing to Manage Chronic Hepatitis B.

Wong GL, Wong VW, Chan HL.

Clin Infect Dis. 2016 Jun 1;62 Suppl 4:S298-305. doi: 10.1093/cid/ciw024.

6.

High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation.

Lee EC, Kim SH, Lee SD, Park H, Lee SA, Park SJ.

World J Gastroenterol. 2016 Apr 14;22(14):3803-12. doi: 10.3748/wjg.v22.i14.3803.

7.

Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B.

Nagata N, Kagawa T, Hirose S, Arase Y, Tsuruya K, Anzai K, Shiraishi K, Mine T.

BMC Gastroenterol. 2016 Mar 17;16:38. doi: 10.1186/s12876-016-0454-z.

8.

HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes.

Lim TH, Gane E, Moyes C, Borman B, Cunningham C.

Hepatol Int. 2016 Sep;10(5):829-37. doi: 10.1007/s12072-016-9709-6. Epub 2016 Mar 8.

PMID:
26957439
9.

Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients.

Yasunaka T, Ikeda F, Wada N, Morimoto Y, Fujioka S, Toshimori J, Kobashi H, Kariyama K, Morimoto Y, Takayama H, Seno T, Takaguchi K, Moriya A, Miyatake H, Okamoto R, Yabushita K, Takaki A, Yamamoto K.

Acta Med Okayama. 2016;70(1):1-12.

10.

PTD-fused p53 as a potential antiviral agent directly suppresses HBV transcription and expression.

Chu X, Wu B, Fan H, Hou J, Hao J, Hu J, Wang B, Liu G, Li C, Meng S.

Antiviral Res. 2016 Mar;127:41-9. doi: 10.1016/j.antiviral.2016.01.008. Epub 2016 Jan 16.

PMID:
26784393
11.

The prognosis and management of inactive HBV carriers.

Invernizzi F, Viganò M, Grossi G, Lampertico P.

Liver Int. 2016 Jan;36 Suppl 1:100-4. doi: 10.1111/liv.13006. Review.

PMID:
26725905
12.

HBV: Do I treat my immunotolerant patients?

Vlachogiannakos J, Papatheodoridis GV.

Liver Int. 2016 Jan;36 Suppl 1:93-9. doi: 10.1111/liv.12996. Review.

PMID:
26725904
13.

Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B.

Jiang DK, Wu X, Qian J, Ma XP, Yang J, Li Z, Wang R, Sun L, Liu F, Zhang P, Zhu X, Wu J, Chen K, Conran C, Zheng SL, Lu D, Yu L, Liu Y, Xu J.

Hepatology. 2016 Apr;63(4):1102-11. doi: 10.1002/hep.28423. Epub 2016 Feb 19.

PMID:
26704347
14.

Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels.

Ahn JM, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW.

PLoS One. 2015 Dec 22;10(12):e0144777. doi: 10.1371/journal.pone.0144777. eCollection 2015.

15.

[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis].

Lian J, Han T, Xiang H, Liu F, Lyu H, Gao Y, Wang F.

Zhonghua Gan Zang Bing Za Zhi. 2015 Oct;23(10):733-7. doi: 10.3760/cma.j.issn.1007-3418.2015.10.005. Chinese.

PMID:
26573188
16.

A Newly Identified Natural Splice Variant ASN Enhances Hepatitis B Virus Amplification.

Zhang X, Zhu S, Zhu W, Li A, Zhu N.

Viral Immunol. 2016 Jan-Feb;29(1):27-32. doi: 10.1089/vim.2015.0044. Epub 2015 Oct 26.

PMID:
26501888
17.
18.

[Associations between hepatitis B virus x gene mutations and hepatocellular carcinoma].

Wang M, Hu Y, Shi W, Wang Q.

Zhonghua Gan Zang Bing Za Zhi. 2015 Aug;23(8):599-603. doi: 10.3760/cma.j.issn.1007-3418.2015.08.009. Chinese.

PMID:
26447624
19.

Hepatitis B: encouraging the use of interferon.

Krishnamoorthy TL, Mutimer D.

Curr Opin Infect Dis. 2015 Dec;28(6):557-62. doi: 10.1097/QCO.0000000000000209. Review.

PMID:
26381998
20.

Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis.

Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF.

Aliment Pharmacol Ther. 2015 Nov;42(10):1182-91. doi: 10.1111/apt.13409. Epub 2015 Sep 18.

Supplemental Content

Loading ...
Support Center